Civamide in OA of the Knee(s)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00077935
Recruitment Status : Completed
First Posted : February 18, 2004
Last Update Posted : June 8, 2011
Information provided by:
Winston Laboratories

Brief Summary:
The purpose of this study is to evaluate the safety of Civamide Cream 0.075% as a Treatment in Subjects with Osteoarthritis (OA) of the Knee(s).

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Drug: Civamide Phase 3

Detailed Description:

This is a 52-week open label study wherein subjects are required to apply the study drug on the knee(s) three times a day. Subjects are required to return to the clinic every 13 weeks.

Enrollment Visit (Day 1) At the End-of-Study/Final Visit, Day 84 of Study No. WL-1001-05-01 (or preferably < 30 days following this visit) subjects will be invited to enroll in this long-term open label Study WL-1001-05-04. Subjects will sign a written informed consent prior to being enrolled into the long-term open label study. If enrolled at the final visit or < 30 days after the final visit of Study No. WL-1001-05-01, the final visit physical examination and laboratory examination will serve as baseline for this study. If enrolled > 30 days after the final visit, a new physical examination and laboratory examination will be completed upon enrollment into this study. The subjects will complete an OA Pain Score and Subject Global Evaluation (SGE) for their Target Knee, the same knee designated as the Target Knee in Study No. WL-1001-05-01. A 13-week supply of study drug and subject diaries for the next 13 weeks will be dispensed to each subject. Instructions on how to apply the study drug will be reviewed with the subjects. Subjects will also be instructed to complete their diaries daily (Adverse Events Log and Other Medications Log) and to return their completed diaries and study drug tubes at each clinic visit.

Treatment Period (Days 1- 365) Subjects will apply study drug to their Target Knee three times a day for 52 weeks. If the subject's other knee is affected by osteoarthritis pain, it may be treated with the study drug as well. The study drug tubes will be weighed prior to being dispensed to the subject. Each tube will also be weighed when the subject returns them.

At each clinic visit, the study staff will review the diaries with each subject for completeness and legibility.

Subjects will complete the OA Pain Score and Subject Global Evaluation at clinic visits on Day 1 and Weeks 13, 26, 39, and 52. Concurrent medications, adverse events, and study drug compliance will be reviewed and recorded by the study staff throughout the Treatment Period at clinic visits on Weeks 13, 26, 39, and 52 (End-of-Study/Final Visit). At the week 52 visit (End-of-Study/Final Visit), a physical examination and laboratory examination will be performed.

On Day 365 (End-of-Study/Final Visit) the subject will be discharged after all procedures have been completed.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 351 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Multicenter Study Evaluating the Safety of Civamide Cream 0.075% as a Treatment in Subjects With Osteoarthritis of the Knee(s)
Study Start Date : November 2003
Actual Primary Completion Date : July 2005
Actual Study Completion Date : July 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Intervention Details:
  • Drug: Civamide
    Cream 0.075%, TID for 52 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 76 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Subject voluntarily agrees to participate in this study and signs an IRB-approved informed consent.
  • Subject has participated (and not withdrawn secondary to any adverse event) in the Phase 3 Osteoarthritis Study WL-1001-05-01 and completed End-of-Study/Final Visit preferably < 30 days prior to Day 1 of this study (WL-1001-05-04).
  • Subject is between 40 and 76 years of age.
  • Subject is generally in good health.
  • Subject is expected to be compliant with study procedures.
  • Female subjects of child-bearing potential must have a negative urine pregnancy test at Day 1.
  • Female subjects of child-bearing potential agree to use an approved form of contraception and must be on the same contraceptive method and dosage schedule during the entire study.

Exclusion Criteria

  • Presence of tendonitis, bursitis, partial or complete joint replacement of knee(s).
  • Presence of active skin disease, erythema, infection, wound, or irritation near the treatment area of the knee(s).
  • Subject has an anticipated need for any surgical or other invasive procedure (e.g., synovial fluid aspiration, arthroscopy, tidal joint irrigation, injectable medications) that will be performed on the knees during the course of the study.
  • Subject has a history and/or diagnosis of rheumatoid arthritis, fibromyalgia, connective tissue disease, psoriatic arthritis, erosive inflammatory OA, diffuse idiopathic skeletal hyperostosis, severe neurologic or vascular disease.
  • Subject has active (redness, swelling, fever, etc.) gout or pseudo-gout within 6 months prior to screening.
  • Subject has Type I or Type II diabetes with peripheral neuropathies.
  • Subject has had trauma or surgery to the knee(s) within 1 year prior to the Enrollment Period.
  • Subject has an underlying clinical condition, including previous malignancies that in the Investigator's judgment, is unstable.
  • Subject has known allergy or hypersensitivity to capsicum, civamide, or capsaicin-containing products or any constituent of the cream formulation.
  • Subject has a history of substance abuse within the past 12 months.
  • Use of certain medications within the given restriction period prior to randomization and during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00077935

  Hide Study Locations
United States, Alabama
Innovative Clinical Trials
Birmingham, Alabama, United States, 35205
United States, Arizona
University of Arizona
Tucson, Arizona, United States, 85724
United States, California
OMC Clinical Research Center
Beverly Hills, California, United States, 90211
Med. Investigations
Fair Oaks, California, United States, 95628
Boling Clinical Trials
Rancho Cucamonga, California, United States, 91730
United States, Florida
Radiant Research
Daytona Beach, Florida, United States, 32114
University Clinical Research
DeLand, Florida, United States, 32720
Robert W. Levin, MD
Dunedin, Florida, United States, 34698
University Clinical Research Inc.
Pembroke Pines, Florida, United States, 33024
United States, Georgia
Radiant Research
Atlanta, Georgia, United States, 30342
United States, Idaho
Radiant Research
Boise, Idaho, United States, 83704
United States, Illinois
Feinberg School of Medicine/Office of Clinical Rsrch and Trng
Chicago, Illinois, United States, 60611
United States, Indiana
Physicians Research Group
Indianapolis, Indiana, United States, 46250
United States, Kansas
Heartland Research Associates
Wichita, Kansas, United States, 67207
United States, Maryland
Chesapeake Medical Research, LLC
Baltimore, Maryland, United States, 21239
United States, Missouri
Center for Pharmaceutical Research
Kansas City, Missouri, United States, 64114
Medex Healthcare Research Inc.
St. Louis, Missouri, United States, 63108
United States, New Jersey
Arthritis Regional Research Center
Mercerville, New Jersey, United States, 08619
United States, New Mexico
New Mexico Research and Osteoporosis Center, Inc.
Albuquerque, New Mexico, United States, 87106
United States, New York
Seligman Center for Advanced Therapeutics
New York, New York, United States, 10003
United States, North Carolina
NC Arthritis and Allergy Care Center
Raleigh, North Carolina, United States, 27609
Raleigh Medical Group, PA
Raleigh, North Carolina, United States, 27609
Piedmont Medical Group
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
University Hospitals of Cleveland
Beachwood, Ohio, United States, 44122
Hightop Medical Research Center
Cincinnati, Ohio, United States, 45224
United States, Pennsylvania
Radiant Research
Philadelphia, Pennsylvania, United States, 19115
Clinical Research Center of Reading, LLP
West Reading, Pennsylvania, United States, 19611
Rheumatic Disease Associates, Ltd.
Willow Grove, Pennsylvania, United States, 19090
United States, South Carolina
Radiant Research
Greer, South Carolina, United States, 29651
United States, Tennessee
Summit Research Solutions
Memphis, Tennessee, United States, 38119
United States, Texas
Radiant Research
Austin, Texas, United States, 78705
United States, Virginia
Arthritis and Rheumatic Diseases
Portsmouth, Virginia, United States, 23701
United States, Washington
Physicians Pharmaceutical Study Services
Everett, Washington, United States, 98201
United States, Wisconsin
Arthritis Clinic
Racine, Wisconsin, United States, 53402
Sponsors and Collaborators
Winston Laboratories
Study Director: Scott B. Phillips, M.D. Winston Laboratories

Responsible Party: Scott B. Phillips, M.D., Study Director, Winston Laboratories, Inc. Identifier: NCT00077935     History of Changes
Other Study ID Numbers: WL-1001-05-04
First Posted: February 18, 2004    Key Record Dates
Last Update Posted: June 8, 2011
Last Verified: February 2004

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs